Faculty, Staff and Student Publications
Publication Date
1-1-2022
Journal
Alzheimer's & Dementia
Abstract
INTRODUCTION: Blood metabolomics-based biomarkers may be useful to predict measures of neurocognitive aging.
METHODS: We tested the association between 707 blood metabolites measured in 1451 participants from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), with mild cognitive impairment (MCI) and global cognitive change assessed 7 years later. We further used Lasso penalized regression to construct a metabolomics risk score (MRS) that predicts MCI, potentially identifying a different set of metabolites than those discovered in individual-metabolite analysis.
RESULTS: We identified 20 metabolites predicting prevalent MCI and/or global cognitive change. Six of them were novel and 14 were previously reported as associated with neurocognitive aging outcomes. The MCI MRS comprised 61 metabolites and improved prediction accuracy from 84% (minimally adjusted model) to 89% in the entire dataset and from 75% to 87% among apolipoprotein E ε4 carriers.
DISCUSSION: Blood metabolites may serve as biomarkers identifying individuals at risk for MCI among US Hispanics/Latinos.
Keywords
global cognitive change, Hispanics/Latinos, metabolite biomarkers, metabolomic risk score, mild cognitive impairment, risk prediction
DOI
10.1002/dad2.12259
PMID
35229015
PMCID
PMC8865745
PubMedCentral® Posted Date
2-23-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Cognition and Perception Commons, Mental and Social Health Commons, Neurology Commons, Public Health Commons